Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Medicinova Inc's Business Segments
Medicinova Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable Segment Aggregation Before Other Operating Segment
Total Revenue
$ 0
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable Segment Aggregation Before Other Operating Segment0%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable Segment Aggregation Before Other Operating Segment | $ 0 | - |
Description of Medicinova Inc
Medicinova Inc. is a biopharmaceutical company headquartered in La Jolla, California. The company is focused on the development and commercialization of innovative therapeutics for the treatment of serious diseases with high unmet medical needs.
Medicinova was founded in 2000 by Dr. Yuichi Iwaki, and has since grown to become a leading player in the field of biopharmaceutical research and development. The company's research projects are primarily focused on developing therapeutics for the treatment of neurological and autoimmune diseases, with an emphasis on neurological disorders such as multiple sclerosis and neurological pain.
Among their most notable products is MN-166 (ibudilast), which has shown promising results in the treatment of a range of neurological disorders, including multiple sclerosis, neuropathic pain, and addiction. Medicinova also has a pipeline of other promising drug candidates, including MN-001 (tipelukast) for the treatment of nonalcoholic steatohepatitis (NASH) and MN-221 (bedoradrine), a selective beta-2 adrenergic receptor agonist for the treatment of acute exacerbations of asthma.
Since its founding, Medicinova has maintained a strong commitment to advancing the development of safe and effective therapeutics for the treatment of debilitating diseases. The company has received numerous awards for its contributions to the biopharmaceutical industry, including the Frost & Sullivan Global Product Line Strategy Leadership Award for MS Therapeutics in 2018.
Medicinova's team of scientists, researchers, and industry experts are driven by a shared commitment to achieving breakthroughs in the treatment of serious diseases, making the company a leader in the biopharmaceutical space.
Medicinova was founded in 2000 by Dr. Yuichi Iwaki, and has since grown to become a leading player in the field of biopharmaceutical research and development. The company's research projects are primarily focused on developing therapeutics for the treatment of neurological and autoimmune diseases, with an emphasis on neurological disorders such as multiple sclerosis and neurological pain.
Among their most notable products is MN-166 (ibudilast), which has shown promising results in the treatment of a range of neurological disorders, including multiple sclerosis, neuropathic pain, and addiction. Medicinova also has a pipeline of other promising drug candidates, including MN-001 (tipelukast) for the treatment of nonalcoholic steatohepatitis (NASH) and MN-221 (bedoradrine), a selective beta-2 adrenergic receptor agonist for the treatment of acute exacerbations of asthma.
Since its founding, Medicinova has maintained a strong commitment to advancing the development of safe and effective therapeutics for the treatment of debilitating diseases. The company has received numerous awards for its contributions to the biopharmaceutical industry, including the Frost & Sullivan Global Product Line Strategy Leadership Award for MS Therapeutics in 2018.
Medicinova's team of scientists, researchers, and industry experts are driven by a shared commitment to achieving breakthroughs in the treatment of serious diseases, making the company a leader in the biopharmaceutical space.
Medicinova Inc. is a prominent pharmaceutical biotechnology research company dedicated to innovating and enhancing health care systems globally. The company operates in three vital segments: neurology, oncology, and autoimmune disorders. Each segment is supported by a diverse portfolio of products and services, meticulously designed to address the specific needs of various medical conditions. The following extensive description outlines the segments, products, and services offered by Medicinova Inc.
Segments
1. Neurology Segment:
Medicinova Inc.s neurology segment focuses on developing novel drugs and therapies for central nervous system disorders. The company prioritizes the treatment of various challenging neurological conditions such as:
- Multiple Sclerosis (MS): A chronic disease affecting the brain and spinal cord, where early intervention is critical.
- Alzheimer’s Disease: A progressive neurodegenerative disorder leading to cognitive decline.
- Parkinson’s Disease: A movement disorder that results from the degeneration of dopamine-producing neurons.
- Cerebral Palsy: A group of disorders affecting movement and muscle tone due to damage to the developing brain.
Medicinova invests significant resources, including time, research efforts, and funding, to conduct comprehensive clinical trials aimed at discovering effective therapies for these disorders. This segment emphasizes the development of drugs that modify disease progression and alleviate symptoms.
2. Oncology Segment:
The oncology segment specializes in the fight against cancer, focusing on a range of malignancies that include:
- Breast Cancer: One of the most common types affecting women, with ongoing research for innovative treatment regimens.
- Pancreatic Cancer: Known for its aggressive nature and difficulty in early detection, leading to the need for urgent therapeutic advancements.
- Leukemia: A cancer of the blood and bone marrow that requires specific and targeted treatment strategies.
- Lung Cancer: The leading cause of cancer-related deaths, where early intervention can significantly alter outcomes.
Medicinova Inc. employs cutting-edge techniques to discover new drug candidates that inhibit tumor growth and progression. The mission of this segment is not only to improve patients survival rates but also to enhance their quality of life by minimizing side effects associated with cancer treatments.
3. Autoimmune Disorder Segment:
This segment addresses conditions where the immune system erroneously attacks healthy cells in the body. Medicinova Inc. focuses on several autoimmune diseases, such as:
- Rheumatoid Arthritis: A chronic inflammatory disorder affecting joints.
- Lupus: A systemic condition that can affect multiple organ systems.
- Crohns Disease: An inflammatory bowel disease that can have severe gastrointestinal implications.
The company conducts extensive research and development to understand the underlying mechanisms of these disorders and to create targeted therapies that can alleviate symptoms and improve patients’ health.
Products
Medicinova Inc. has developed an array of innovative therapies aimed at treating various health conditions. Key products include:
1. MN-166 (Ibudilast):
MN-166 is a patented glial modulator being explored for its ability to treat neurological disorders, including Multiple Sclerosis and Amyotrophic Lateral Sclerosis (ALS). It shows promise in preventing the progression of progressive multiple sclerosis (PMS), a condition currently lacking approved treatment options.
2. MN-001 (Tipelukast):
This product acts as a selective neutrophil elastase inhibitor and is in clinical development for a variety of conditions, such as non-alcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF), and lupus. MN-001 is designed to target inflammation and fibrosis relevant to these diseases.
3. MN-221 (Bedoradrine):
MN-221 is a selective beta-3-adrenoreceptor agonist that offers rapid onset of action for acute treatment scenarios, such as in asthma attacks and hypotension. Its mechanism allows for quick therapeutic effects, essential in emergency situations.
4. MN-305 (Cantrixil):
Currently under investigation for the treatment of ovarian cancer, MN-305 targets the mitochondria of cancer cells, inhibiting tumor growth through a unique mechanism of action that is still being explored in clinical settings.
Services
Medicinova Inc. provides a range of services tailored to support the development of effective pharmaceuticals.
1. Clinical Trial Services:
The company conducts a variety of clinical trials designed to evaluate the safety and efficacy of its products. Medicinova collaborates with experienced clinical investigators to ensure comprehensive trial management and data collection, facilitating advancements in patient care.
2. Research Services:
A significant portion of Medicinova’s resources is directed towards research aimed at understanding disease mechanisms and identifying new therapeutic targets. The research team focuses on cutting-edge methodologies to innovate and identify potential treatments, ensuring that the companys pipeline remains robust and responsive to patient needs.
Conclusion
Medicinova Inc. is a leader in the pharmaceutical biotechnology sector, with a firm commitment to addressing the health care challenges posed by neurological disorders, cancer, and autoimmune diseases. Its extensive product offerings and dedicated research services reflect its mission to improve patient outcomes through innovative therapeutic solutions and continued advancement in clinical science.
Segments
1. Neurology Segment:
Medicinova Inc.s neurology segment focuses on developing novel drugs and therapies for central nervous system disorders. The company prioritizes the treatment of various challenging neurological conditions such as:
- Multiple Sclerosis (MS): A chronic disease affecting the brain and spinal cord, where early intervention is critical.
- Alzheimer’s Disease: A progressive neurodegenerative disorder leading to cognitive decline.
- Parkinson’s Disease: A movement disorder that results from the degeneration of dopamine-producing neurons.
- Cerebral Palsy: A group of disorders affecting movement and muscle tone due to damage to the developing brain.
Medicinova invests significant resources, including time, research efforts, and funding, to conduct comprehensive clinical trials aimed at discovering effective therapies for these disorders. This segment emphasizes the development of drugs that modify disease progression and alleviate symptoms.
2. Oncology Segment:
The oncology segment specializes in the fight against cancer, focusing on a range of malignancies that include:
- Breast Cancer: One of the most common types affecting women, with ongoing research for innovative treatment regimens.
- Pancreatic Cancer: Known for its aggressive nature and difficulty in early detection, leading to the need for urgent therapeutic advancements.
- Leukemia: A cancer of the blood and bone marrow that requires specific and targeted treatment strategies.
- Lung Cancer: The leading cause of cancer-related deaths, where early intervention can significantly alter outcomes.
Medicinova Inc. employs cutting-edge techniques to discover new drug candidates that inhibit tumor growth and progression. The mission of this segment is not only to improve patients survival rates but also to enhance their quality of life by minimizing side effects associated with cancer treatments.
3. Autoimmune Disorder Segment:
This segment addresses conditions where the immune system erroneously attacks healthy cells in the body. Medicinova Inc. focuses on several autoimmune diseases, such as:
- Rheumatoid Arthritis: A chronic inflammatory disorder affecting joints.
- Lupus: A systemic condition that can affect multiple organ systems.
- Crohns Disease: An inflammatory bowel disease that can have severe gastrointestinal implications.
The company conducts extensive research and development to understand the underlying mechanisms of these disorders and to create targeted therapies that can alleviate symptoms and improve patients’ health.
Products
Medicinova Inc. has developed an array of innovative therapies aimed at treating various health conditions. Key products include:
1. MN-166 (Ibudilast):
MN-166 is a patented glial modulator being explored for its ability to treat neurological disorders, including Multiple Sclerosis and Amyotrophic Lateral Sclerosis (ALS). It shows promise in preventing the progression of progressive multiple sclerosis (PMS), a condition currently lacking approved treatment options.
2. MN-001 (Tipelukast):
This product acts as a selective neutrophil elastase inhibitor and is in clinical development for a variety of conditions, such as non-alcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF), and lupus. MN-001 is designed to target inflammation and fibrosis relevant to these diseases.
3. MN-221 (Bedoradrine):
MN-221 is a selective beta-3-adrenoreceptor agonist that offers rapid onset of action for acute treatment scenarios, such as in asthma attacks and hypotension. Its mechanism allows for quick therapeutic effects, essential in emergency situations.
4. MN-305 (Cantrixil):
Currently under investigation for the treatment of ovarian cancer, MN-305 targets the mitochondria of cancer cells, inhibiting tumor growth through a unique mechanism of action that is still being explored in clinical settings.
Services
Medicinova Inc. provides a range of services tailored to support the development of effective pharmaceuticals.
1. Clinical Trial Services:
The company conducts a variety of clinical trials designed to evaluate the safety and efficacy of its products. Medicinova collaborates with experienced clinical investigators to ensure comprehensive trial management and data collection, facilitating advancements in patient care.
2. Research Services:
A significant portion of Medicinova’s resources is directed towards research aimed at understanding disease mechanisms and identifying new therapeutic targets. The research team focuses on cutting-edge methodologies to innovate and identify potential treatments, ensuring that the companys pipeline remains robust and responsive to patient needs.
Conclusion
Medicinova Inc. is a leader in the pharmaceutical biotechnology sector, with a firm commitment to addressing the health care challenges posed by neurological disorders, cancer, and autoimmune diseases. Its extensive product offerings and dedicated research services reflect its mission to improve patient outcomes through innovative therapeutic solutions and continued advancement in clinical science.